13F Holdings
中文EN

HELP Helus Pharma Inc. IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1833141 · Reporting currency CAD · Fiscal year ends 03/31

Financial factors as of 2025-03-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY-44.9%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-42.8%
ROA-40.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets8.3%
Debt / equity0.00x
Current ratio7.75x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-4.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: CAD FY2025*2025-03-31FY2024*2024-03-31FY2023*2023-03-31FY2022*2022-03-31FY2021*2021-03-31
Income statement
Revenue———0864,000
Cost of revenue———0664,000
Gross profit———0200,000
R&D expense54.91M32.36M25.49M17.59M3.30M
SG&A expense45.37M32.59M21.34M28.22M15.87M
Income tax00000
Net income-113.14M-78.08M-47.49M-67.63M-32.22M
EPS (basic)-5.59-9.41-0.26-0.40-0.32
EPS (diluted)——-0.26-0.40-0.32
Balance sheet
Cash & equivalents135.02M208.99M16.63M53.64M64.03M
Receivables5.88M4.48M3.05M2.10M1.33M
Current assets165.97M218.54M23.18M58.35M66.48M
PP&E, netmay include right-of-use assets (IFRS)141,000266,000450,000491,000557,000
Goodwill51.49M47.48M24.79M22.89M23.37M
Intangibles41.02M35.47M5.47M2.08M1.70M
Total assets258.62M302.02M53.90M84.06M92.11M
Current liabilities21.42M10.10M5.66M7.91M4.90M
Total liabilities21.42M10.10M5.66M7.91M5.99M
Shareholders' equity237.20M291.93M48.23M76.16M86.12M
Cash flow statement
Operating cash flow-101.30M-68.91M-47.43M-45.21M-19.03M
Capital expenditure—21,000142,000105,000135,000
Free cash flow—-68.93M-47.57M-45.31M-19.16M
Investing cash flow-1.97M6.92M-3.31M-770,000-1.19M
Financing cash flow20.20M254.51M13.56M35.78M82.72M
Depreciation & amortization475,000424,000251,000——
Stock-based compensation42.87M13.89M4.69M18.03M11.55M

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.